Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tuaminoheptane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.76 |
| ▸ | TP53 | P04637 | 1/20 | 0.72 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.52 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.50 |
| ▸ | GABRP | O00591 | 2/20 | 0.50 |
| ▸ | GABRD | O14764 | 2/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.50 |
| ▸ | GABRE | P78334 | 2/20 | 0.50 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tuaminoheptane SCHEMBL8359697 | 1.00 | OPRM1 (0.76) | OPRM1TP53GRIK1GRIK2SLC1A2 | |
| Tuaminoheptane SCHEMBL25287775 | 1.00 | OPRM1 (0.76) | OPRM1TP53GRIK1GRIK2SLC1A2 | |
| Bicarbonate SCHEMBL9188645 | 0.98 | OPRM1 (0.73) | OPRM1TP53GRIK1GRIK2SLC1A2 | |
| Tuaminoheptane SCHEMBL5568060 | 0.93 | OPRM1 (0.73) | OPRM1TP53GRIK1GRIK2SLC1A2 | |
| Bicarbonate SCHEMBL6548682 | 0.93 | OPRM1 (0.64) | OPRM1TP53GRIK1GRIK2SLC1A2 | |
| Carbamic Acid SCHEMBL28702337 | 0.91 | OPRM1 (0.70) | OPRM1TP53GRIK1GRIK2SLC1A2 | |
| Acetic Acid SCHEMBL5575019 | 0.91 | OPRM1 (0.70) | OPRM1TP53GRIK1GRIK2SLC1A2 | |
| Acetic Acid SCHEMBL8094686 | 0.89 | OPRM1 (0.67) | OPRM1TP53GRIK1GRIK2SLC1A2 | |
| Propionic Acid SCHEMBL5571670 | 0.89 | OPRM1 (0.67) | OPRM1TP53GRIK1GRIK2GPR84 | |
| SCHEMBL5574135 | 0.89 | OPRM1 (0.67) | OPRM1TP53GRIK1GRIK2SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041622-A1 | Compositions containing aminoalkanes and aminoalkane derivatives | VIRUN, INC. | 2010-02-18 | — | — | US | disclosed |
| WO-2010019255-A1 | COMPOSITIONS CONTAINING AMINOALKANES AND AMINOALKANE DERIVATIVES | VIRUN, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| EP-0991626-A2 | PYRIMIDIN-2,4,6-TRION DERIVATIVES, METHOD FOR PRODUCING THE SAME AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS | Roche Diagnostics GmbH (DE) | 2000-04-12 | — | — | EP | disclosed |
| WO-1998058915-A2 | PYRIMIDIN-2,4,6-TRION DERIVATIVES AND THEIR USE AS METALLOPROTEASE-INHIBITORS | ROCHE DIAGNOSTICS GMBH (DE) | 1998-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041622-A1 | Compositions containing aminoalkanes and aminoalkane derivatives | TAAR5, PDE3A, PDE2A | OPRM1 116/4885TP53 4500/4885GRIK1 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.